Efficacy of mifepristone in reducing intermenstrual vaginal bleeding in users of the levonorgestrel intrauterine system

Abstract

Mifepristone was effective in reducing the number of episodes and duration of intermenstrual bleeding/spotting in LNG-IUS users.

A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52‐mg levonorgestrel intrauterine system

“…Abnormal uterine bleeding during use of the LNG-IUS or subdermal implants is the main cause of early removal for both contraceptives. 12 The common treatments tested so far have proven unsuccessful at resolving this situation. If UPA is adequate for treating LNG-IUS users who experience abnormal bleeding, this could be a major therapeutic advance.…”

“…[7][8][9][10] Several treatments have been used to control abnormal bleeding in LNG-IUS users; however, all have proved unsuccessful. [11][12][13] Although tranexamic acid, nonsteroidal anti-inflammatory drugs, mifepristone, and estrogens reduce abnormal uterine bleeding, their effectiveness for treating abnormal bleeding in LNG-IUS users is still under debate. [11][12][13] Ulipristal acetate (UPA) is a selective progesterone receptor modulator (SPRM), which presents agonist and antagonist actions.…”

“…[11][12][13] Although tranexamic acid, nonsteroidal anti-inflammatory drugs, mifepristone, and estrogens reduce abnormal uterine bleeding, their effectiveness for treating abnormal bleeding in LNG-IUS users is still under debate. [11][12][13] Ulipristal acetate (UPA) is a selective progesterone receptor modulator (SPRM), which presents agonist and antagonist actions. It acts as an agent on myometrial, endometrial, and ovarian tissue.…”

Therapeutic Options for Unscheduled Bleeding Associated with Long-Acting Reversible Contraception

“…Satisfaction with the IUD was also higher in the treatment group, 75% versus 44% (P 5 .004). 21 Mifepristone is most commonly used as part of a regimen for medical abortion and is available in 200-mg tablets. Mifepristone is not currently available as a lower dose, and the expense of this mediation makes it impractical now.…”

Translational research in women's health: From bedside to bench and from bench to bedside

“…Currently, clinical trials with CDB-2914 for the treatment of uterine myomas are taking place in Europe, with favorable outcomes. Since uterine myoma is the most common benign tumor during reproductive years, it is hoped that this translational research-and other similar translation research based on clinical observations and new drug and therapeutic developments [20]-will contribute to significant improvements in women's health.…”